Analyst firms · Leerink Partners · ADAP
Leerink Partners ADAP price target and rating history
Adaptimmune Therapeutics plc (ADAP) · Health Care
Leerink Partners rates Adaptimmune Therapeutics plc (ADAP) Market Perform with a $7 price target, as of its latest action on Sep 13, 2021. It has published 3 rating actions on ADAP since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Market Perform
- Price target
- $7
- Median target, all firms
- Too few
- Actions on ADAP
- 3
Leerink Partners price target on ADAP
Every Leerink Partners rating on ADAP
- Sep 13, 2021
- Sep 7, 2021
- Aug 10, 2021
Questions about Leerink Partners and ADAP
- What is Leerink Partners's price target for ADAP?
- Leerink Partners's latest stated price target for Adaptimmune Therapeutics plc (ADAP) is $7, from its action on Sep 13, 2021.
- What is Leerink Partners's rating on ADAP?
- Leerink Partners rates ADAP Market Perform, a neutral rating, as of Sep 13, 2021.
- When did Leerink Partners last change its view on ADAP?
- On Sep 13, 2021, Leerink Partners raises its price target to $7 from $6, keeps Market Perform.
All Leerink Partners ratingsADAP news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.